Skip to Main Content
Pitt Home
Find People
School of Medicine
Toggle navigation
Skip Navigation Links
Home
About
Leadership
Mission
Department Statistics
Building Information
Thomas E. Starzl BST
Biomedical Science Tower 3
Conference Rooms
BSTWR E1347 - Wingard/Lazo Conference Room
BSTWR 1395
Shops
Cell Biology/Pharmacology Machine Shop
Directory
Primary Faculty
Secondary Faculty
Graduate Students
Fellows
Administrative Staff
Research Staff
Adjunct Faculty
Department Alumni
Research
Research Areas
Labs
Equipment
Non-PC&B Personnel Core Facilities Access Request
Funding Opportunities
Faculty Development Program
Responsible Conduct of Research
Education
Molecular Pharmacology Graduate Program
Current Students
Current Student Roster
Student Publications
Diversity, Accessibility, and Counseling
Student Awards
MPGP News
Student Poster and Presentation Resources
Prospective Students
Welcome from the Director
Research Opportunities
PhD Track
MD/PhD Track
Financial Aid
Graduate Faculty
Admin Staff
Graduate Courses
Lab Rotations
Events
Grad Student Event Calendar
Graduate Student Event Schedule
Alumni/Career Development
Alumni
Alumni Contacts
Molecular Pharmacology Facebook Group
Molecular Pharmacology Student-Alumni Network (LinkedIn)
SOM Graduate Studies - Career and Professional Development
Executive Committee
Student Testimonials
IBGP
Funding Opportunities
NIH T32 Training Grant
Outcomes
Predoctoral Fellowship
Admissions
Student Handbook & General Timeline
Links
Useful Links
School of Medicine
PubMed
Remote Resources
Biomedical Masters Program
Undergraduate Research
Summer Fellowships
Lab Rotations
Graduate Fellowships
News
Events
Calendar
Seminar Series
Links
Contact
Opportunities
Department
PORtal
Computer Resources Access Request
IT-Equipment-Facilities Support Request
Poster Requests
Reservation Calendars
Badge Access Request
Home
>
Research
>
Labs
>
George Lab
George Lab
Current Members
Research
Alumni
Publications
Sharon A. George, PhD
Dr. Sharon George leads the HEART Lab – Heart Engineering: Arrhythmia Research and Therapy Lab, in the Department of Pharmacology and Chemical Biology at the University of Pittsburgh. Research in the HEART Lab can be broadly divided into the following foci:
Cardio-Oncology:
Cardiovascular diseases have long been the leading cause of death, not only in the US but also worldwide. Decades of research in this field have led to a decline in the rate of cardiovascular deaths but recently an uptick in this statistic was observed. One factor that could contribute to this increase is related to cancer and its treatment. It has long been known that most cancer chemotherapy drugs and radiation therapy have significant cardiotoxic effects that can lead to heart failure or myocarditis and death. Recent studies have also demonstrated that cancer by itself can increase the risk of cardiac diseases such as atrial fibrillation and vice versa. Thus, it is very important to understand the interaction of these two major human diseases. This led to the rise of the new field of cardio-oncology.
The HEART Lab focuses on the role of cardiac metabolism in the development of chemotherapy-induced cardiotoxicity. Impaired metabolism is a hallmark of cardiotoxicity associated with several classes of chemotherapeutic agents. Yet, there are currently no effective cardioprotective strategies to protect the heart. The research in our lab focuses on two methods of cardioprotection by preserving metabolism, 1) exercise, and 2) molecular targets of metabolism.
Aerobic exercise is known to improve cardiac metabolism and thus could be cardioprotective. In the exercise study, we use a mouse model of treadmill running during chemotherapy as well as an in vitro exercise model for our human cardiac slices. The benefits of exercise on cardiac electrical, mechanical and metabolic functions are assessed by echocardiography, electrocardiography, optical mapping and seahorse analysis. Our results indicate that 1) exercise by itself modulates cardiac function and 2) during chemotherapy exercise has a cardioprotective role. Our recent study, indicates that exercise by itself causes significant electrical remodeling and increased risk of developing arrhythmias (aberrant electrical rhythms). The benefits of exercise during chemotherapy and the mechanisms underlying these cardioprotective effects are under investigation.
Alternatively, our group is studying molecular targets in the heart that can be activated to prevent chemotherapy-induced metabolic impairment. This new direction of research includes both mouse and human heart models. Transgenic knockout and overexpression mouse models and pharmacological agonists and antagonists are being tested in study. More details coming soon.
Sex-specific mechanisms of cardiac diseases and therapy:
A preponderance of recent evidence suggests that cardiac physiology and the progression of cardiac pathophysiology is sex-specific. Premenopausal women are at a lower risk of developing life threatening cardiovascular diseases compared to age-matched men. This phenomenon is typically attributed to the protective effects of estrogen, which is higher in premenopausal women.
Our cardio-oncology studies identified that there is a significant sex dimorphism in the way that adult female hearts respond to cancer chemotherapy compared to male hearts. The HEART Lab aims to understand the contribution of the sex hormones, estrogen, progesterone and testosterone, in modulating cardiac physiology and pathophysiology. We use mice and human cardiac slice models treated with varying combinations of the above sex hormones. Mice with physiologic hormone profiles as well as gonadectomized mice with reverse hormone profiles are used in this study, along with similarly treated human cardiac slices. The cardiotoxicity of chemotherapeutic drugs are tested in each of these conditions. While males are typically associated with increased morbidity after chemotherapy, we expect to see opposite effect in the reverse hormone profile mice. The functional effects and mechanistic pathways involved in this hormonal regulation of chemotherapy-induced cardiotoxicity are under investigation. The results of this study could have significant impacts in determining chemotherapy and diagnosing cardiotoxicity in a sex-specific manner. More importantly, it could highlight the need to understand the cardiac response to hormonal therapies.
Human Cardiac Organotypic slices:
The HEART Lab works with human donor hearts that are not used in transplantation. These human hearts can be used as whole heart preparations, coronary perfused wedge preparations and organotypic cardiac slice preparations, to study human cardiac physiology and pathophysiology. Of particular interest to the HEART Lab is the organotypic cardiac slices which are generated from the atria or ventricles in the heart at a thickness of up to 400 microns. These slices contain cardiomyocytes in their native environment along with other cardiac cell types and are an excellent tool for preclinical drug testing and translation of findings from animal research to the clinic. These slice preparations can be cultured over several days or weeks which allow the study of both acute and chronic effects of drugs on cardiac physiology. Dr. George has used this platform to test the effects of cancer chemotherapeutic agents such as doxorubicin, sunitinib, and other drugs such as dantrolene and relaxin.
Multi-parametric optical mapping of cardiac physiology and pathophysiology:
Optical mapping is an imaging technique used to measure cardiac function from living tissue which can range from cells to whole hearts. To study the complex, multi-faceted phenomenon that is cardiac physiology and pathophysiology, the HEART Lab uses multi-parametric imaging systems to simultaneously measure parameters of cardiac metabolism (NADH and FAD), excitation (transmembrane potential) and contraction (intracellular calcium transients) from the same field of view. This allows the study of the modulation of these individual parameters and the interrelationship between them called metabolism-excitation-contraction coupling (MEC coupling).
Sharon A. George, PhD
Assistant Professor
Sharon A. George, PhD
Journal Articles
SA George
, JA Brennan-McLean, KA Trampel, E Rytkin, NR Faye, BC Knollmann and IR Efimov. Ryanodine receptor inhibition with acute dantrolene treatment reduces arrhythmia susceptibility in human hearts. Am J Physiol Heart Circ Physiol 325:H720-H728, 2023.
SA George
, KA Trampel, K Brunner and IR Efimov. Moderate endurance exercise increases arrhythmia susceptibility and modulates cardiac structure and function in a sexually dimorphic manner. bioRxiv, 2023. doi: https://doi.org/10.1101/2023.08.21.554195
SA George
, A Kiss, KA Trampel, S Obaid, L Tang, IR Efimov and T Efimova. Anthracycline cardiotoxicity is exacerbated by global p38b genetic ablation in a sexually dimorphic manner but unaltered by cardiomyocyte-specific p38alpha loss. Am J Physiol Heart Circ Physiol 325:H983-H997, 2023.
SA George
, Z Lin and IR Efimov. Simultaneous triple-parametric optical mapping of transmembrane potential, intracellular xalcium and NADH for cardiac physiology assessment. Commun Biology 5:319, 2022.
A Warhol,
SA George
, SN Obaid, T Efimova and IR Efimov. Differential cardiotoxic electrocardiographic response to doxorubicin treatment in conscious versus anesthetized mice. Physiol Rep 9:e14987, 2021.
SA George
, A Kiss, SN Obaid, Ai Venegas, T Talapatra, T Efimova and IR Efimov. p38delta genetic ablation protects female mice from anthracycline cardiotoxicity. Am J Physiol Heart Circ Physiol 319:H775-H786, 2020.
SA George
, JA Brennan and IR Efimov. Preclinical ardiac electrophysiology assessment by dual voltage and calcium optical mapping of human organotypic cardiac slices. J Vis Exp, 2020